...
首页> 外文期刊>Breast Cancer: Targets and Therapy >The role of the chemokine receptor XCR1 in breast cancer cells
【24h】

The role of the chemokine receptor XCR1 in breast cancer cells

机译:趋化因子受体XCR1在乳腺癌细胞中的作用

获取原文

摘要

Considerable attention has recently been paid to the application of chemokines to cancer immunotherapy due to their complex role in cell proliferation, invasion, metastasis, and tumorigenesis, which extends beyond the regulation of lymphocyte migration during immune responses. The expression and the function of the chemokine receptor XCR1 on breast cancer have remained elusive to date. In this study, the expressions of XCR1 mRNA were tested by quantitative real-time polymerase chain reaction in one breast epithelial cell line (MCF-10A) and nine breast cancer cell lines (MDA-MB-231, 231HM, 231BO, MDA-MB-468, MCF-7, T47D, Bcap-37, ZR-75-30, and SK-BR-3). We established XCR1-overexpressing breast cancer cell line MDA-MB-231 (231/XCR1) in XCR1 low expression cell line MDA-MB-231 (231). The ability of proliferation, invasion, and metastasis was measured by CCK8, plate cloning formation, and transwell analysis, respectively, in XCR1-overexpressing breast cancer cell lines (231/XCR1) and their parental cell line MDA-MB-231/Vector (simplified as “231/Vector”); 5×106/100 μL cells were inoculated in mammary fat pad of BALB/c nude mice. There were six BALB/c nude mice in the experimental group and control group. Protein expression was analyzed by cell immunofluorescence and Western blot. The growth of XCR1-overexpressing human breast cancer cell line MDA-MB-231 in vitro was restrained and tumorigenesis in vivo was also extenuated, its mechanism may involve in the inhibition of MAPK and PI3K/AKT/mTOR signaling pathway, but increase in LC3 expression. However, the overexpression of XCR1 in human breast cancer cell line MDA-MB-231 in vitro can promote the migration and invasion partially due to decreasing the protein level of β-catenin. Therefore, XCR1 can affect the biological characteristics of some special breast cancer cells through complex signal transduction pathway.
机译:由于趋化因子在细胞增殖,侵袭,转移和肿瘤发生中具有复杂作用,因此趋化因子在癌症免疫治疗中的应用已引起了广泛关注,其作用超出了免疫应答过程中淋巴细胞迁移的调控范围。迄今为止,趋化因子受体XCR1在乳腺癌中的表达和功能尚不清楚。在这项研究中,通过定量实时聚合酶链反应在一个乳腺癌上皮细胞系(MCF-10A)和九个乳腺癌细胞系(MDA-MB-231、231HM,231BO,MDA-MB)中测试了XCR1 mRNA的表达。 -468,MCF-7,T47D,Bcap-37,ZR-75-30和SK-BR-3)。我们在XCR1低表达细胞系MDA-MB-231(231)中建立了XCR1过表达的乳腺癌细胞系MDA-MB-231(231 / XCR1)。在XCR1过表达的乳腺癌细胞系(231 / XCR1)及其亲代细胞系MDA-MB-231 / Vector中,分别通过CCK8,平板克隆形成和transwell分析来测量其增殖,侵袭和转移能力。简化为“ 231 / Vector”);将5×10 6 / 100μL细胞接种到BALB / c裸鼠的乳腺脂肪垫中。实验组和对照组有六只BALB / c裸鼠。通过细胞免疫荧光和蛋白质印迹分析蛋白质表达。 XCR1过表达的人乳腺癌细胞MDA-MB-231的体外生长受到抑制,体内肿瘤发生也得到减轻,其机制可能与抑制MAPK和PI3K / AKT / mTOR信号通路有关,但在LC3中增加表达。然而,XCR1在人乳腺癌细胞系MDA-MB-231中的过表达在体外可以部分促进迁移和侵袭,这是由于降低了β-catenin的蛋白质水平。因此,XCR1可通过复杂的信号转导途径影响某些特殊乳腺癌细胞的生物学特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号